CRVO_OUT_1 [2025-03-21 13:50:18 -0400] 1972 Bytes | 574 tokens | Cum: 574 tkns (7.17% of 8k)
==========================================================================

Alright, let’s light it up, because it's 1:50:17 PM on Fri Mar 21, 2025 -0400, and I'm charging into CervoMed (CRVO), popping from 11.56 to 14.02. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for CervoMed:

C1 - Mar-19-25 04:27PM - Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?
C2 - Mar-18-25 04:48AM - CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now
C3 - Mar-17-25 08:00AM - CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
C4 - Mar-17-25 08:00AM 07:28AM - Why CervoMed Inc. (CRVO) Soared Last Week?
C5 - Mar-14-25 11:25AM - CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program
C6 - Mar-10-25 04:05PM - CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
C7 - Feb-19-25 02:09PM - Why CervoMed (CRVO) Is Advancing Today
C8 - Jan-31-25 08:00AM - CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on CervoMed (CRVO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CRVO_OUT_3 [2025-03-21 13:50:24 -0400] 1047 Bytes | 306 tokens | Cum: 882 tkns (11.03% of 8k)
==========================================================================

Showing C3 (chunk 1 of 11): C3:
**CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates**
Date: Mar-17-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/17/3043647/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html

March 17, 2025 08:00 ET| Source:CervoMed Inc.CervoMed Inc.

-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure-

-Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities-

-Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation-

BOSTON, March 17, 2025 (GLOBE NEWSWIRE) --  CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing tre

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CRVO_OUT_5 [2025-03-21 13:50:26 -0400] 906 Bytes | 277 tokens | Cum: 1161 tkns (14.51% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-21T17:05:38Z - 12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASD...
A2 - 2025-03-21T11:52:29Z - CervoMed Q1 EPS Increased by Brookline Capital Management...
A3 - 2025-03-21T11:52:28Z - Roth Capital Issues Negative Outlook for CervoMed Earnings...
A4 - 2025-03-20T17:06:07Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - Akebia Therapeutics (NASDAQ:AKBA), Ada...
A5 - 2025-03-19T14:37:42Z - CervoMed (NASDAQ:CRVO) Price Target Raised to $20.00...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CRVO_OUT_7 [2025-03-21 13:50:27 -0400] 1038 Bytes | 319 tokens | Cum: 1482 tkns (18.52% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASDAQ:CRVO)**Date: 2025-03-21Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44440699/12-health-care-stocks-moving-in-fridays-intraday-sessionGainers Impact BioMedical IBO stock increased by 98.1% to $4.12 during Friday's regular session. The company's market cap stands at $47.4 million. TransCode Therapeutics RNAZ stock moved upwards by 60.9% to $1.24. Galecto GLTO shares increased by 40.09% to $5.8. The market value of their outstanding shares is at $7.6 million. As per the press release, Q4 earnings came out 2 days ago. Regencell Bioscience RGC stock increased by 30.36% to $58.67. The market value of their outstanding shares is at $763.4 million. Tonix Pharmaceuticals TNXP stock moved upwards by 26.71% to $23

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CRVO_OUT_9 [2025-03-21 13:50:29 -0400] 1026 Bytes | 308 tokens | Cum: 1792 tkns (22.40% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-29T13:00:00Z - CervoMed to Present at the 8th International Lewy Body Dementia Conference
B2 - 2024-10-02T12:00:00Z - CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
B3 - 2024-06-11T12:00:00Z - CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
B4 - 2024-04-08T12:00:36Z - Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
B5 - 2024-04-01T12:00:00Z - CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
B6 - 2024-03-28T12:30:00Z - CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_11 [2025-03-21 13:50:33 -0400] 621 Bytes | 189 tokens | Cum: 1983 tkns (24.79% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/11/2896702/0/en/CervoMed-Announces-Completion-of-Enrollment-in-Phase-2b-RewinD-LB-Clinical-Trial-of-Neflamapimod-for-the-Treatment-of-Patients-with-Dementia-with-Lewy-Bodies.html- Topline data expected in December 2024 -

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CRVO_OUT_13 [2025-03-21 13:50:34 -0400] 1083 Bytes | 289 tokens | Cum: 2326 tkns (29.07% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S2 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S3 - 2025-03-17 10-K ITEM 7.

MGT S DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

##TABLE_END

This discussion and analysis contains information related to historical and prospective events intended to enable you to assess our financial condition and results of ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_15 [2025-03-21 13:50:39 -0400] 981 Bytes | 240 tokens | Cum: 2568 tkns (32.10% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act....

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CRVO_OUT_17 [2025-03-21 13:50:51 -0400] 4284 Bytes | 1232 tokens | Cum: 3908 tkns (48.85% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Volume: 6,133,226 | SMA50: 326.71% | Market Cap: 122.27M | Option/Short: No / No | Sales past 5Y: 7.26% | Sales Surprise: 40.76% |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 4.48M | SMA200: 31.65% | Shs Outstand: 8.70M | Short Float: 16.04% | Employees: 15 | EPS Surprise: -24.55% |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 2.12 | Perf Week: 118.17% | Shs Float: 5.64M | Short Ratio: 0.20 | Debt/Eq: 0.00 | P/E: - |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| RSI (14): 95.22 | Perf Month: 504.30% | Inst Own: 17.08% | Short Interest: 0.90M | Sales Y/Y TTM: 142.42% | Earnings: Mar 17 BMO |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.37 | Perf Quarter: 624.23% | Insider Own: 35.20% | Beta: -0.11 | ROE: -69.95% | |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| SMA20: 186.22% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: -13.19% | ROI: -41.56% | |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: CervoMed Inc. Common Stock
Market Cap: 120876036.945
Shares Outstanding: 8253741
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9737974.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -16290695.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 14.4
Average Volume: 11506213.74
30-Day High: 14.4
30-Day Low: 2.12

[Detailed Financials: TTM 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: TTM 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,206,650.0

[Detailed Financials: FY 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: FY 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,206,650.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CRVO_OUT_19 [2025-03-21 13:50:53 -0400] 676 Bytes | 167 tokens | Cum: 4309 tkns (53.86% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CRVO_IN_21 [2025-03-21 13:50:55 -0400] 126 Bytes | 29 tokens | Cum: 4366 tkns (54.57% of 8k)
==========================================================================

====================================
[2025-03-21 10:50:55] # Analysis Completed
Elapsed Time: 38.08 seconds